Immunocore Limited announces appointment of Dr Jonathan Knowles to the Board

Immunocore Limited announces appointment of Dr Jonathan Knowles to the Board

Company set to move into clinical development stage

(Oxford, UK) 1st February 2010.  Immunocore Limited, the Oxford-based pioneer of T cell receptor technology, announces the appointment of Dr Jonathan Knowles to the Board as a non-executive director with immediate effect.

 

Dr. Knowles has had a distinguished career in academia and in the pharmaceutical industry. Dr Knowles stepped down from his executive positions at the end of 2009 and this is one of the first non executive positions he has taken up.

 

Dr Knowles held the position of President of Group Research and Member of the Executive Committee at F.Hoffman-LaRoche Limited, Basel, Switzerland for 12 years. He also served as a Board member at Genentech Inc for over ten years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, Dr Knowles was Research Director, Glaxo Wellcome Europe.

 

Dr Knowles has also served as Chairman of the EFPIA research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a Joint Undertaking with the EU Commission), He is Chairman of the Hever Group, Professor at EPFL, Switzerland, a Distinguished Professor at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a William Pitt Fellow of Pembroke College, Cambridge.

 

Commenting on the appointment, Nicholas Cross, Chairman of Immunocore, said:

"We are delighted that someone as distinguished as Jonathan has chosen to become a director of Immunocore as the company moves into clinical development. He will provide us with invaluable advice on our unique T cell receptor pipeline in the years to come."

 

Commenting, Dr Knowles said:

"Immunocore has a truly revolutionary new technology, with the potential to provide novel and highly effective medicines for serious diseases such as cancer. I am very excited at becoming part of the Immunocore team."

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.